OPKO Health (OPK) Competitors $1.35 -0.01 (-0.74%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$1.37 +0.02 (+1.48%) As of 07/11/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock OPK vs. LGND, FOLD, BCRX, CLDX, DVAX, INVA, MNKD, NVAX, GERN, and RGLSShould you be buying OPKO Health stock or one of its competitors? The main competitors of OPKO Health include Ligand Pharmaceuticals (LGND), Amicus Therapeutics (FOLD), BioCryst Pharmaceuticals (BCRX), Celldex Therapeutics (CLDX), Dynavax Technologies (DVAX), Innoviva (INVA), MannKind (MNKD), Novavax (NVAX), Geron (GERN), and Regulus Therapeutics (RGLS). These companies are all part of the "biotechnology" industry. OPKO Health vs. Its Competitors Ligand Pharmaceuticals Amicus Therapeutics BioCryst Pharmaceuticals Celldex Therapeutics Dynavax Technologies Innoviva MannKind Novavax Geron Regulus Therapeutics Ligand Pharmaceuticals (NASDAQ:LGND) and OPKO Health (NASDAQ:OPK) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, institutional ownership, risk, earnings, analyst recommendations, dividends, media sentiment and profitability. Do analysts prefer LGND or OPK? Ligand Pharmaceuticals currently has a consensus price target of $147.17, suggesting a potential upside of 20.93%. OPKO Health has a consensus price target of $2.75, suggesting a potential upside of 103.70%. Given OPKO Health's higher probable upside, analysts plainly believe OPKO Health is more favorable than Ligand Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ligand Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00OPKO Health 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.00 Which has more volatility and risk, LGND or OPK? Ligand Pharmaceuticals has a beta of 0.84, indicating that its stock price is 16% less volatile than the S&P 500. Comparatively, OPKO Health has a beta of 1.34, indicating that its stock price is 34% more volatile than the S&P 500. Which has better earnings & valuation, LGND or OPK? Ligand Pharmaceuticals has higher earnings, but lower revenue than OPKO Health. OPKO Health is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLigand Pharmaceuticals$167.13M14.05-$4.03M-$7.12-17.09OPKO Health$713.10M1.50-$53.22M-$0.07-19.29 Is LGND or OPK more profitable? OPKO Health has a net margin of -5.66% compared to Ligand Pharmaceuticals' net margin of -73.07%. OPKO Health's return on equity of -2.85% beat Ligand Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Ligand Pharmaceuticals-73.07% -7.83% -6.92% OPKO Health -5.66%-2.85%-1.82% Does the media favor LGND or OPK? In the previous week, Ligand Pharmaceuticals had 5 more articles in the media than OPKO Health. MarketBeat recorded 12 mentions for Ligand Pharmaceuticals and 7 mentions for OPKO Health. OPKO Health's average media sentiment score of 1.05 beat Ligand Pharmaceuticals' score of 0.69 indicating that OPKO Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ligand Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive OPKO Health 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals have more ownership in LGND or OPK? 91.3% of Ligand Pharmaceuticals shares are held by institutional investors. Comparatively, 64.6% of OPKO Health shares are held by institutional investors. 7.0% of Ligand Pharmaceuticals shares are held by company insiders. Comparatively, 49.7% of OPKO Health shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. SummaryOPKO Health beats Ligand Pharmaceuticals on 10 of the 16 factors compared between the two stocks. Get OPKO Health News Delivered to You Automatically Sign up to receive the latest news and ratings for OPK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OPK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OPK vs. The Competition Export to ExcelMetricOPKO HealthMED INSTRUMENTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.07B$6.73B$5.55B$9.09BDividend YieldN/A1.29%5.07%4.03%P/E Ratio-19.2826.3028.2520.31Price / Sales1.5065.25433.2199.68Price / Cash19.6220.6826.2427.98Price / Book0.684.648.125.50Net Income-$53.22M$174.76M$3.19B$250.38M7 Day Performance0.37%-1.00%3.62%4.79%1 Month Performance1.50%0.99%5.98%9.59%1 Year Performance-2.17%5.27%29.39%16.41% OPKO Health Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OPKOPKO Health4.0152 of 5 stars$1.35-0.7%$2.75+103.7%-2.2%$1.07B$713.10M-19.282,997News CoverageAnalyst UpgradeLGNDLigand Pharmaceuticals4.0823 of 5 stars$113.76-0.7%$146.14+28.5%+22.4%$2.19B$167.13M-15.9880News CoverageInsider TradeFOLDAmicus Therapeutics4.1241 of 5 stars$6.05-0.8%$16.22+168.1%-41.5%$1.86B$528.29M-67.21480News CoverageAnalyst RevisionBCRXBioCryst Pharmaceuticals4.2053 of 5 stars$8.76-2.0%$16.70+90.6%+22.5%$1.83B$450.71M-33.69530CLDXCelldex Therapeutics2.491 of 5 stars$20.94-4.8%$50.11+139.3%-42.4%$1.39B$7.56M-7.76150DVAXDynavax Technologies4.3759 of 5 stars$10.30+0.3%$24.00+133.0%-1.6%$1.24B$277.25M-19.81350News CoverageINVAInnoviva4.0943 of 5 stars$18.91-1.6%$55.00+190.9%+12.2%$1.19B$369.84M-18.72100News CoverageAnalyst ForecastAnalyst RevisionMNKDMannKind2.4381 of 5 stars$3.54-1.7%$10.33+191.9%-33.9%$1.08B$285.50M35.40400Negative NewsNVAXNovavax4.3505 of 5 stars$6.61-2.8%$17.00+157.2%-47.8%$1.07B$682.16M2.491,990GERNGeron3.3488 of 5 stars$1.37-4.2%$5.06+269.5%-72.0%$872.58M$76.99M-6.5270News CoverageAnalyst ForecastGap DownRGLSRegulus Therapeutics1.5014 of 5 stars$8.16flat$8.50+4.2%N/A$564.92MN/A-11.1830 Related Companies and Tools Related Companies LGND Competitors FOLD Competitors BCRX Competitors CLDX Competitors DVAX Competitors INVA Competitors MNKD Competitors NVAX Competitors GERN Competitors RGLS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OPK) was last updated on 7/13/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OPKO Health, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share OPKO Health With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
